Stockreport

Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline

IPSEN SA S/ADR  (IPSEY) 
NASDAQ:AMEX Investor Relations: ipsen.com/investors
PDF Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response [Read more]